Atara Biotherapeutics(US:ATRA) ZACKS·2024-08-12 23:10Company Performance - Atara Biotherapeutics reported a quarterly loss of $3.10 per share, significantly worse than the Zacks Consensus Estimate of a loss of $1.25, representing an earnings surprise of -148% [1] - The company's revenues for the quarter ended June 2024 were $28.64 million, missing the Zacks Consensus Estimate by 40.70%, compared to revenues of $0.96 million in the same quarter last year [1] - Over the last four quarters, Atara Biotherapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [1] Stock Performance - Atara Biotherapeutics shares have declined approximately 40.9% since the beginning of the year, contrasting with the S&P 500's gain of 12% [2] - The current Zacks Rank for Atara Biotherapeutics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$7 on revenues of $5.71 million, and for the current fiscal year, it is -$15.75 on revenues of $106.64 million [4] - The trend of estimate revisions for Atara Biotherapeutics is mixed, and future changes in estimates will be closely monitored following the recent earnings report [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Atara Biotherapeutics belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook [5] - Praxis Precision Medicines, Inc., another company in the same industry, is expected to report a quarterly loss of $2.38 per share, reflecting a year-over-year change of +67.6% [5][6]